Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
133
resultados
Última actualización
09/03/2025 [06:54:00]
Resultados 25 a 50 de 133
Resumen de: AU2023341648A1
Systems, devices, and methods for a dual analyte sensor using glucose history from a glucose sensor in combination with data from a ketone sensor to control operation of a user interface device or insulin pump are provided. In some embodiments, the systems, apparatus or methods may make use of combination of glucose history and a β-hydroxybutyrate physiological model to better predict diabetic ketoacidosis (DKA), in comparison to a prediction based on a simple high glucose threshold. In other embodiments, the systems, apparatus or method may include features for generating an estimate of the patient's medication state and/or knowledge of medication information, such as a patient with T1 diabetes mellitus (DM) using an SGLT-2 inhibitor.
Resumen de: WO2025041079A1
The present invention relates to an automatic diabetic foot scanner (1), comprising of, a housing (2), a control unit (3), a communication module (4). The housing (2) accommodates a plurality of modules for detecting a diabetic foot and said plurality of modules are operated by a single on-chip board (18). The plurality of modules include a neuropathy assessment module (5), a blood circulation assessment module (6) and a plantar pressure measurement module (7). Further, the present invention is a cost friendly and portable solution of detecting diabetic foot.
Resumen de: EP4512325A1
A continuous glucose monitor, comprising a housing and a circuit board arranged in the housing, wherein an electronic component is carried on the circuit board; a probe assembly configured to penetrate skin and connected to the circuit board; and an auxiliary sensor connected to the circuit board and configured to detect a compressed state of the continuous glucose monitor. The continuous glucose monitor provided in the present disclosure can identify its own compressed state, thereby improving the accuracy of glucose measurement.
Resumen de: EP4512328A2
The present invention relates to a body attachment unit for continuous glucose monitoring. The present invention provides a body attachment unit for continuous glucose monitoring, wherein: the body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus separate additional work is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by a user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.
Resumen de: EP4512332A2
An improved sensor set is provided for sensing of a body characteristic, such as glucose. The sensor set includes a mounting base for the sensor and a connector to connect to the mounting base. The connector may contain sensor electronics for wired or wireless communication to an external monitor or display. The mounting base includes a connector fitting adapted to fit into a tubular recess in the connector, wherein the connector fitting includes a key. In some embodiments, the proximal end of the sensor folds around the key such that there are contact pads on both sides of the key. The mounting base and connector include additional features, such as pegs and prongs that allow for unique fitting of compatible mounting bases and connectors, while locking out non-compatible components.
Resumen de: EP4512327A1
An embodiment may provide a method for calibrating sensitivity for glucose measurement including: obtaining (S1201) an offset value for determining sensitivity; determining (S1203) a first sensitivity from a sensor data and a reference glucose value, based on the offset value; and determining (S1205) sensitivity by adjusting the first sensitivity, wherein the determining of the sensitivity includes obtaining the first sensitivity, and determining (S1205-1) sensitivity A by adjusting the first sensitivity according to an elapsed period of time after a sensor is inserted into a body; obtaining the first sensitivity, and determining (S1205-1) sensitivity B by adjusting the first sensitivity by reflecting an average sensor data obtained by averaging a plurality of sensor data and an average glucose value obtained by averaging a plurality of glucose values to the first sensitivity; and determining (S1205-2) any one of the sensitivity A and the sensitivity B as the sensitivity.
Resumen de: EP4512326A1
An embodiment may provide a method for calibrating sensitivity for glucose measurement including: obtaining (S1201) an offset value for determining sensitivity; determining (S1203) a first sensitivity from a sensor data and a reference glucose value, based on the offset value; and determining (S1205) sensitivity by adjusting the first sensitivity, wherein the determining (S1205) of the sensitivity includes obtaining one sensitivity, and determining (S1205-1) sensitivity A by adjusting the one sensitivity by reflecting an average sensor data obtained by averaging a plurality of sensor data and an average glucose value obtained by averaging a plurality of glucose values to the one sensitivity; and determining (S1205-2) the sensitivity A as the sensitivity.
Resumen de: EP4513510A1
This application provides a blood glucose assessment method, an electronic device, and a computer-readable storage medium. The method is applied to a wearable device, and includes: collecting vital sign data of a user in a first cycle of blood glucose assessment; performing blood glucose assessment on the user based on valid vital sign data in the vital sign data, to obtain a blood glucose assessment result corresponding to the first cycle; displaying the blood glucose assessment result corresponding to the first cycle; and automatically starting a next cycle of the blood glucose assessment. According to the technical solutions of this application, blood glucose assessment can be periodically and automatically performed, helping reduce operation complexity for the user.
Resumen de: EP4513503A2
The subject matter disclosed herein provides methods for presenting glucose level data. Glucose data for a patient may be received. A current glucose level and a rate of change of the current glucose level may be determined based on the received glucose data. A first interface may be displayed on a screen of a device. The first interface may include a unitary icon. The unitary icon may display the current glucose level and a visualization of the rate of change. Related apparatus, systems, techniques, and articles are also described.
Resumen de: JP2024137994A
To provide analyte sensors that are responsive to at least two analytes of interest using a single enzyme-based analyte sensor.SOLUTION: Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, the analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol-responsive active area to detect glucose and ethanol in vivo.SELECTED DRAWING: Figure 9A
Resumen de: US2025057448A1
The present invention relates to a device (12) for determining a state of health of a patient (11), comprising: an input interface (16) for receiving a glucose measurement value with information relating to a glucose level of the patient and a glucose uptake input value with information relating to a glucose uptake of the patient; an estimation unit (18) for determining the state of health of the patient on the basis of the received values and a predefined state model, which represents the state of health of the patient by means of a state vector and using a plurality of model parameters, wherein the state vector comprises a glucose model value with information relating to the glucose level of the patient and can comprise an insulin model value with information relating to the insulin level of the patient; a comparison unit (20) for determining a deviation between the glucose measurement value and the glucose model value; and an individualization unit (22) for the patient-specific update of a model parameter on the basis of the determined deviation. Further model parameters can comprise individual glucose or insulin sensitivities, the incretin sensitivity and sensitivities with respect to lifestyle input values. The present invention also relates to a system (10) and to a method for determining a state of health of a patient (11).
Resumen de: US2025058041A1
Disclosed herein are techniques related to predicting a physiological condition of a user. In some embodiments, the techniques may involve obtaining one or more glucose concentration values measured from a user; applying, to the one or more glucose concentration values measured from the user, a first glucose prediction model for a first prediction horizon; obtaining, based on applying the first glucose prediction model, a first predicted glucose value of the user; and predicting a second predicted glucose value of the user for a second prediction horizon that is less than the first prediction horizon, based on the first predicted glucose value and at least one glucose concentration value of the one or more glucose concentration values. In some scenarios, the physiological condition may include, for example, hypoglycemia or hyperglycemia.
Resumen de: US2025058042A1
The exemplary embodiments may provide a correction factor (CF) for a user that is dynamically adjustable based on current glucose level. In some exemplary embodiments, the CF of the user is adjusted based on the current glucose level of the user. As the current glucose level of the user increases to be above a threshold, the CF may be adjusted to reflect a decrease in the insulin sensitivity of the user. This adjustment may cause the control system to increase the amount of insulin delivered to the user as the glucose level of the user exceeds the threshold. Similarly, the CF of the user may be adjusted based on the current target glucose level of the user or based on a combination of the current glucose level of the user and the current target glucose level of the user.
Resumen de: US2025058039A1
An infusion system comprising: a device for delivering insulin to a user, the device configured to be mounted the user; a CGM sensor for measuring glucose level in the user and an infusion needle for delivering the insulin to the user; a needle cartridge assembly for supporting the CGM sensor and/or the infusion needle, the needle cartridge assembly configured to move from (1) a telescoping position above the device for delivering insulin, wherein the CGM sensor and/or infusion needle are/is in a retracted position within the device for delivering insulin to (2) an advanced position within the device, wherein the infusion needle and/or CGM sensor are/is in a deployed position inserted into a subcutaneous tissue of the user's skin; and a detachable activation mechanism for (a) moving the needle cartridge assembly from the telescoping position to the advanced position and for (b) releasing the device for delivering insulin upon activation of the detachable activation by the user.
Resumen de: AU2023342848A1
Systems, devices and methods are provided for incorporating a medication delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. The integrated management system may produce a plurality of reports that may include data related to analyte levels (e.g., glucose levels) and medication delivered (e.g., insulin delivered). The integrated system may also include a mode in which certain types of data are no longer shared and/or stored if the user is not signed into an account. The types of data shared and/or stored when the user is not signed into an account may differ from the types of data shared and/or stored when the user is signed into an account.
Resumen de: US2025062595A1
This disclosure describes a glucose monitor with one or more photonic crystal surface-emitting lasers (PCSELs). The PCSEL comprises a plurality of photonics crystal sections. Each photonics crystal section is operable to emit light of a different wavelength. The horizontal emission by each photonics crystal section may be constrained by edge lattice sections.
Resumen de: WO2025038566A1
The exemplary embodiments may provide a correction factor (CF) for a user that is dynamically adjustable based on current glucose level. In some exemplary embodiments, the CF of the user is adjusted based on the current glucose level of the user. As the current glucose level of the user increases to be above a threshold, the CF may be adjusted to reflect a decrease in the insulin sensitivity of the user. This adjustment may cause the control system to increase the amount of insulin delivered to the user as the glucose level of the user exceeds the threshold. Similarly, the CF of the user may be adjusted based on the current target glucose level of the user or based on a combination of the current glucose level of the user and the current target glucose level of the user.
Resumen de: WO2025037363A1
A skin phantom (1) is obtained by laminating a porous film (3) on a hydrogel (2) comprising a gelling agent, glucose, an electrolyte, and water. The porous film (3) is one that is impregnated with a hydrophobic material or one in which a hydrophobic material is formed on the surface of the porous film (3) on the side in contact with the hydrogel (2).
Resumen de: MX2023009042A
Disclosed herein is an implantable glucose sensor (1, 1', 1'', 1''', 1'''') for determining impedance in tissue of a living being, the implantable glucose sensor comprises: - a housing (2, 2'), - two injecting electrodes (4, 4') for injecting current into the tissue, - two sensing electrodes (5) for measuring impedance in the tissue, whereby the two sensing electrodes (5) are arranged separately from the two injecting electrodes (4, 4'), - a coil (7) arranged within the housing (2, 2') for powering the implantable glucose sensor via a power source (10), - a circuit board (8) arranged within the housing (2, 2'), the circuit board (8) being electrically connected to the two sensing electrodes (5) and the two injecting electrodes (4, 4') and the coil (7), - a communication unit (9) for transferring and receiving data packages, the communication unit (9) being connected to the circuit board (8), and wherein the housing (2) comprises a first part (3a) and a second part (3b, 3b'). The two sensing electrodes (5) and the two injecting electrodes (4, 4') are arranged on an outer surface of the first part (3a). The outer surface of first part (3a) is of a convex shape and in that the two sensing electrodes (5) and the two injecting electrodes (4, 4') are embedded in the convex shape so that they are flush with the outer surface of the convex shape.
Resumen de: EP4509045A1
A blood glucose prediction method and device combining a big data model and a personalized model. The method comprises: training a big data blood glucose prediction model; receiving a first collection data set of a specified object; when a first data type is a label type, according to the first collection data set, updating a personalized data base; if the updating is successful, counting the total number of personalized data records to generate a first total number; if the first total number is greater than or equal to a first threshold value, screening personalized data calibrated records; if the first total number is equal to a second threshold value, training a personalized blood glucose prediction model; when the first data type is a prediction type, counting the total number of personalized data records to generate a second total number; if the second total number is smaller than the second threshold value, on the basis of the big data blood glucose prediction model, making a prediction; and if the second total number is equal to the second threshold value, on the basis of the big data blood glucose prediction model and the personalized blood glucose prediction model, making a personalized blood glucose prediction. The method can avoid the inconvenience of invasive blood glucose tests.
Resumen de: EP4509049A1
A lancing and blood glucose level measuring device includes a casing; a laser oscillation unit that is accommodated within the casing and configured to generate a laser beam for blood sampling; a blood glucose level measuring unit that is accommodated within the casing and configured to measure a blood glucose level; a contact unit that is formed on a part of one side of the casing and configured to irradiate the laser beam toward an irradiation target area; a blood glucose strip insertion unit which is formed on another part of one side of the casing and into which a blood glucose strip including a blood glucose sensor that transmits and receives signals to and from the blood glucose level measuring unit to measure a blood glucose level is to be inserted; and a controller configured to control the laser oscillation unit.
Resumen de: EP4510398A2
This disclosure describes a glucose monitor with one or more photonic crystal surface-emitting lasers (PCSELs). The PCSEL comprises a plurality of photonics crystal sections. Each photonics crystal section is operable to emit light of a different wavelength. The horizontal emission by each photonics crystal section may be constrained by edge lattice sections.
Resumen de: EP4509046A2
Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.
Resumen de: US2025049353A1
An estimation system comprises at least one processor; and at least one non-transitory medium connected to the at least one processor. The at least one processor is programmed to perform acquiring input information including a pulse wave of a first subject; and estimating the blood glucose level or a glucose metabolism of the first subject based on an estimation expression. The estimation expression is based on a blood glucose level and a pulse wave corresponding to the blood glucose level, and based on a result of regression analysis using an Augmentation Index given by a ratio of a magnitude of a forward wave of the pulse wave and a reflected wave emerging after the forward wave.
Nº publicación: US2025049397A1 13/02/2025
Solicitante:
BIOLINQ INCORPORATED [US]
Biolinq Incorporated
Resumen de: US2025049397A1
Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable.
BOPI
Sede Electrónica
